Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 12/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074667 | 0.83 | KDM4E (0.51) | KDM4EGAAMAPTCYP1A2CYP2C19 | |
| SCHEMBL13818364 | 0.82 | P2RY1 (0.57) | P2RY1P2RY14 | |
| SCHEMBL5133684 | 0.78 | KDM4E (0.47) | KDM4EGAAMAPTCYP1A2CYP2C19 | |
| SCHEMBL30079615 | 0.78 | KEAP1 (0.53) | KDM4EGAAMAPTCYP1A2CYP2C19 | |
| SCHEMBL397428 | 0.78 | KEAP1 (0.53) | KDM4EGAAMAPTCYP1A2CYP2C19 | |
| SCHEMBL10256222 | 0.76 | P2RY1 (0.50) | KDM4EMAPTP2RY1P2RY14ALDH1A1 | |
| SCHEMBL11924510 | 0.75 | MAPT (0.48) | KDM4EGAAMAPTCYP1A2CYP2C19 | |
| SCHEMBL13990727 | 0.74 | KMT2A (0.56) | KDM4EGAAMAPTL3MBTL1P2RY1 | |
| SCHEMBL821369 | 0.73 | TDP1 (0.50) | MAPTP2RY1ALDH1A1 | |
| SCHEMBL10256056 | 0.73 | ALDH1A1 (0.46) | MAPTCYP1A2CYP2C19CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-03 | — | — | US | disclosed |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-05 | — | — | US | disclosed |
| US-20150293078-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2015-10-15 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-9090619-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-01-29 | — | — | US | disclosed |
| US-8242149-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-14 | — | — | US | disclosed |
| US-8101767-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-22 | — | — | US | disclosed |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090246820-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-10 | — | — | US | disclosed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20150031722-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20100184739-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20090227797-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885GAA 969/4885MAPT 4731/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KDM4E 4337/4885GAA 344/4885MAPT 4347/4885 |
| US-20150065487-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20090298876-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20150315186-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885GAA 969/4885MAPT 4731/4885 |
| US-20160318931-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | KDM4E 4262/4885GAA 454/4885MAPT 4269/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | KDM4E 4552/4885GAA 733/4885MAPT 4775/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | KDM4E 4481/4885GAA 969/4885MAPT 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.